Sputtr.com | Alternative Search Engine

Bardoxolone

Pablo E. Pergola, M.D., Ph.D., Philip Raskin, M.D., Robert D ...

The new england journal of medicine n engl j med 365;4 nejm.org july 28, 2011 327 original article Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

Bardoxolone Methyl and Kidney Function in CKD with Type 2 ...

The new england journal of medicine 10.1056/nejmoa 1105351 nejm.org 1 original article Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes Pablo E. Pergola, M.D., Ph.D., Philip Raskin, M.D., Robert D. Toto, M.D., Colin J. Meyer, M.D., J. Warren Huff, J.D., Eric B. Grossman, M.D ...

BARDOXOLONE, A NOVEL ORAL ANTIINFLAMMATORY AGENT SHOWN TO ...

BARDOXOLONE, A NOVEL ORAL ANTIINFLAMMATORY AGENT SHOWN TO IMPROVE RENAL FUNCTION Colin Meyer, Reata Pharmaceuticals, Irving, TX, USA.

Bardoxolone methyl BEAM study

" Bardoxolone methyl (also known as "RTA 402" and "CDDO-methyl ester") is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class.

Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug ...

Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug Bardoxolone Methyl to Kyowa Hakko Kirin $272 Million Deal for Asian Territories IRVING, TX and Tokyo, Japan -- January 7, 2010-- Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that ...

Kidney News - December 2010

Pablo Pergola, research director for Renal Associates PA and of the University of Texas Health Science Center, San Antonio, presented findings from a Phase IIb trial of bardoxolone methyl in CKD patients with type 2 diabetes.

Bardoxolone, a Novel Oral Anti- Inflammatory Agent Improves ...

Bardoxolone, a Novel Oral Anti-Inflammatory Agent Improves Glycemic Control in Type 2 Diabetics with Chronic Kidney Disease SherwynSchwartz, M.D., Douglas Denham, D.O., Craig Hurwitz, M.D., Colin Meyer, M.D., Pablo Pergola, M.D., Ph.D.

National Kidney Foundation Spring Clinical Meetings 2010 ...

Phase 2b/3 Trial Design and Baseline Patient Characteristics of a Study to Determine Effects of Bardoxolone Methyl (BARD) in Patients with Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD) PE Pergola, EB Grossman, C Meyer, B Richardson, D Warnock Renal Associates, PA, San Antonio, TX; Reata ...

Table of Contents*

RTA 401; CDDO Bardoxolone Methyl[2008] (bardox'oh lone meth'il). C 32 H 43 NO 4. 505.70. (1) Oleana-1,9(11)-dien-28-oicacid, 2-cyano-3,12-dioxo-, methyl ester; (2) (รพ)-Methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate.

Abbott Pipeline Highlights

... Women's Health Elagolix : Finalizing Phase III design for endometriosis; finalizing Phase II design for uterine fibroids Immunology Humira new indications provide significant incremental sales potential; also investigating small molecules and combination biologics Chronic Kidney Disease (CKD) Bardoxolone in ...